Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190303421 | Liver | HCC | regulation of response to wounding | 94/7958 | 167/18723 | 2.19e-04 | 1.66e-03 | 94 |
GO:00060732 | Liver | HCC | cellular glucan metabolic process | 46/7958 | 73/18723 | 3.23e-04 | 2.28e-03 | 46 |
GO:00440422 | Liver | HCC | glucan metabolic process | 46/7958 | 73/18723 | 3.23e-04 | 2.28e-03 | 46 |
GO:20001421 | Liver | HCC | regulation of DNA-templated transcription, initiation | 28/7958 | 40/18723 | 4.01e-04 | 2.71e-03 | 28 |
GO:00602601 | Liver | HCC | regulation of transcription initiation from RNA polymerase II promoter | 24/7958 | 33/18723 | 4.24e-04 | 2.85e-03 | 24 |
GO:009030321 | Liver | HCC | positive regulation of wound healing | 38/7958 | 59/18723 | 5.61e-04 | 3.61e-03 | 38 |
GO:003239211 | Liver | HCC | DNA geometric change | 54/7958 | 90/18723 | 6.04e-04 | 3.79e-03 | 54 |
GO:00062824 | Liver | HCC | regulation of DNA repair | 74/7958 | 130/18723 | 6.27e-04 | 3.89e-03 | 74 |
GO:000632511 | Liver | HCC | chromatin organization | 206/7958 | 409/18723 | 7.23e-04 | 4.41e-03 | 206 |
GO:007030222 | Liver | HCC | regulation of stress-activated protein kinase signaling cascade | 105/7958 | 195/18723 | 8.79e-04 | 5.20e-03 | 105 |
GO:00708971 | Liver | HCC | transcription preinitiation complex assembly | 25/7958 | 36/18723 | 9.87e-04 | 5.71e-03 | 25 |
GO:190303621 | Liver | HCC | positive regulation of response to wounding | 44/7958 | 72/18723 | 1.10e-03 | 6.32e-03 | 44 |
GO:004586021 | Liver | HCC | positive regulation of protein kinase activity | 194/7958 | 386/18723 | 1.16e-03 | 6.54e-03 | 194 |
GO:00063021 | Liver | HCC | double-strand break repair | 131/7958 | 251/18723 | 1.17e-03 | 6.54e-03 | 131 |
GO:003249611 | Liver | HCC | response to lipopolysaccharide | 174/7958 | 343/18723 | 1.19e-03 | 6.62e-03 | 174 |
GO:00712166 | Liver | HCC | cellular response to biotic stimulus | 128/7958 | 246/18723 | 1.53e-03 | 8.10e-03 | 128 |
GO:001095012 | Liver | HCC | positive regulation of endopeptidase activity | 96/7958 | 179/18723 | 1.68e-03 | 8.79e-03 | 96 |
GO:003367411 | Liver | HCC | positive regulation of kinase activity | 230/7958 | 467/18723 | 1.72e-03 | 8.95e-03 | 230 |
GO:003287222 | Liver | HCC | regulation of stress-activated MAPK cascade | 102/7958 | 192/18723 | 1.86e-03 | 9.49e-03 | 102 |
GO:00712226 | Liver | HCC | cellular response to lipopolysaccharide | 110/7958 | 209/18723 | 1.92e-03 | 9.77e-03 | 110 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HMGB1 | SNV | Missense_Mutation | | c.120N>C | p.Glu40Asp | p.E40D | P09429 | protein_coding | deleterious(0.02) | benign(0.105) | TCGA-D8-A1XT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin+cyclophosphamide | SD |
HMGB1 | SNV | Missense_Mutation | | c.131A>C | p.Lys44Thr | p.K44T | P09429 | protein_coding | deleterious(0.02) | possibly_damaging(0.784) | TCGA-A6-6780-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
HMGB1 | SNV | Missense_Mutation | | c.624A>T | p.Glu208Asp | p.E208D | P09429 | protein_coding | tolerated_low_confidence(0.26) | benign(0) | TCGA-AA-3821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HMGB1 | SNV | Missense_Mutation | | c.443C>G | p.Ala148Gly | p.A148G | P09429 | protein_coding | deleterious(0.01) | probably_damaging(0.983) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
HMGB1 | SNV | Missense_Mutation | novel | c.377C>T | p.Ala126Val | p.A126V | P09429 | protein_coding | deleterious(0.03) | benign(0.221) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HMGB1 | SNV | Missense_Mutation | novel | c.168G>T | p.Glu56Asp | p.E56D | P09429 | protein_coding | deleterious(0.04) | benign(0.105) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
HMGB1 | SNV | Missense_Mutation | | c.253N>G | p.Thr85Ala | p.T85A | P09429 | protein_coding | tolerated(0.15) | benign(0.009) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HMGB1 | SNV | Missense_Mutation | novel | c.23N>G | p.Lys8Arg | p.K8R | P09429 | protein_coding | deleterious(0.02) | benign(0.358) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
HMGB1 | SNV | Missense_Mutation | novel | c.25N>T | p.Pro9Ser | p.P9S | P09429 | protein_coding | deleterious(0.04) | possibly_damaging(0.573) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HMGB1 | SNV | Missense_Mutation | | c.488G>A | p.Arg163Gln | p.R163Q | P09429 | protein_coding | tolerated(0.16) | benign(0.193) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3146 | HMGB1 | DRUGGABLE GENOME, CELL SURFACE, TRANSCRIPTION FACTOR | | PREDNISOLONE | PREDNISOLONE | 18447956 |
3146 | HMGB1 | DRUGGABLE GENOME, CELL SURFACE, TRANSCRIPTION FACTOR | | AUTOLOGOUS DENDRITIC CELLS | | 16997859 |
3146 | HMGB1 | DRUGGABLE GENOME, CELL SURFACE, TRANSCRIPTION FACTOR | | ADJUVANT | | 15161015 |
3146 | HMGB1 | DRUGGABLE GENOME, CELL SURFACE, TRANSCRIPTION FACTOR | | SALINE | SODIUM CHLORIDE | 17334244 |
3146 | HMGB1 | DRUGGABLE GENOME, CELL SURFACE, TRANSCRIPTION FACTOR | | DISTAMYCIN | | 9161031 |
3146 | HMGB1 | DRUGGABLE GENOME, CELL SURFACE, TRANSCRIPTION FACTOR | | GP100 | | 16968820 |
3146 | HMGB1 | DRUGGABLE GENOME, CELL SURFACE, TRANSCRIPTION FACTOR | | CHLORAMPHENICOL | CHLORAMPHENICOL | 9931456 |
3146 | HMGB1 | DRUGGABLE GENOME, CELL SURFACE, TRANSCRIPTION FACTOR | | EGCG | EPIGALOCATECHIN GALLATE | 17987129 |
3146 | HMGB1 | DRUGGABLE GENOME, CELL SURFACE, TRANSCRIPTION FACTOR | | MART1 | | 16968820 |
3146 | HMGB1 | DRUGGABLE GENOME, CELL SURFACE, TRANSCRIPTION FACTOR | | AMPICILLIN | AMPICILLIN | 9931456 |